Gold Or Platinum Patents (Class 424/649)
  • Patent number: 10386359
    Abstract: Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 20, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS), INSTITUT DE CANCERLOGIE DE L'OUEST—SITE RENE GAUDUCHEAU
    Inventors: Francois Paris, Nolwenn Dubois, Emmanuel Rio, Natacha Ripoche
  • Patent number: 10300026
    Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 28, 2019
    Assignees: Shanxi Yabao Health Products Co., Ltd., Yabao Pharmaceutical Group Co., Ltd.
    Inventors: Jianguo Zhang, Wuxian Ren, Peng Wang, Bangqin Ya
  • Patent number: 10280178
    Abstract: Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 7, 2019
    Assignees: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Bum Joon Park, Gyu Yong Song, Ah-Young Oh, Jee-Hyun Lee, Jin-Hyuk Her
  • Patent number: 10265294
    Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: April 23, 2019
    Assignee: Yale University
    Inventors: Gil G. Mor, Ayesha Alvero
  • Patent number: 10251842
    Abstract: Nanocapsules of bioactive compounds derived from natural products as an adjunct treatment for cancer. Nanocapsules of bioactive compounds showed synergy in the treatment of cancer therapy-induced toxicity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: April 9, 2019
    Assignee: King Abdulaziz University
    Inventors: Amna Ali Nasser Saddiq, Shaker Ahmad Mousa, Deena Shaker Mousa
  • Patent number: 10213449
    Abstract: Provided are methods and compositions for treating an individual who has a medulloblastoma. Methods for treating an individual who has a medulloblastoma tumor can include a step of administering to the individual, at a dose sufficient to reduce the size and/or growth rate of the medulloblastoma tumor, a composition that includes a casein kinase II (CK2) inhibitor (e.g., a CK2-selective inhibitor such as CX-4945). In some cases, the medulloblastoma tumor is a hedgehog-dependent medulloblastoma tumor. In some cases, the medulloblastoma tumor is a hedgehog-independent medulloblastoma tumor. In some cases, the medulloblastoma tumor is smoothened inhibitor-resistant (SMO inhibitor-resistant). In some cases, the medulloblastoma is resistant to treatment with 4,5,6,7-tetrabromo-2H-benzotriazole (TBB). In some cases, the dose is sufficient to cause long term regression of the medulloblastoma tumor, and in some cases, the dose is sufficient to increase the chance of survival of the individual.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: February 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Teresa Purzner, Matthew Peter Scott
  • Patent number: 10155006
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: December 18, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10145824
    Abstract: An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with refractive index (RI) detection; the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: December 4, 2018
    Assignee: Del Mar Pharmaceuticals (BC) Ltd.
    Inventor: Xiaoyun Liu
  • Patent number: 10072021
    Abstract: Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: September 11, 2018
    Assignees: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Bum Joon Park, Gyu Yong Song, Ah-Young Oh, Jee-Hyun Lee, Jin-Hyuk Her
  • Patent number: 10066003
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10052304
    Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form H2O2, and one or more anti-cancer therapies.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: August 21, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Bryan G. Allen, Douglas R. Spitz, Garry R. Buettner, Joseph Cullen, Joshua Schoenfeld, Michael Schultz, Fenghuang Zhan
  • Patent number: 9994843
    Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: June 12, 2018
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Johji Inazawa, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki
  • Patent number: 9963452
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: AUGUSTA PHARMACEUTICALS INC.
    Inventors: Dorre A. Grueneberg, Ori Kalid, Jun Xian, Sharanappa B. Rajur, Hwa-Ok Kim, Venugopal Rao Neelagiri, Paresh Salgaonkar, Divakaramenon Sethumadhavan, Chaeho Moon, Madhavi Neelagiri
  • Patent number: 9950025
    Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of muramyl dipeptide, and their use in the treatment of neoplastic disease.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 24, 2018
    Assignee: Innate Immunotherapeutics Limited
    Inventors: Frank B. Gelder, Gillian Alison Webster
  • Patent number: 9895366
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: February 20, 2018
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Xu
  • Patent number: 9884086
    Abstract: Disclosed is a method for providing information used for comparing restoration rates of damaged DNA, wherein information about a time period when Ataxia telangiectasia and Rad3 related (‘ATR’) activation is accelerated, on the basis of alternative information about an expression level of cryptochrome may be acquired, therefore, it can be determined that a restoration rate of damaged DNA is high at a time period when the expression level of cryptochrome is high. Accordingly, a time period when a restoration rate of DNA damaged by different causes is high, can be determined. Further, it is possible to estimate a time period when side effects occurring due to using an anticancer drug are minimized, and then, utilize the estimated result in determining the timing of administration of an anticancer drug.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 6, 2018
    Assignee: DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY—ACADEMY COOPERATION
    Inventors: Tae Hong Kang, Jeong Min Park, Ji Ye Choi, Sun Hee Leem
  • Patent number: 9821008
    Abstract: Compositions and methods for inhibiting the DNA repair protein complex, ERCC1-XPF, and methods to enhance clinical responses to anticancer drugs that interact with DNA such as cisplatin, and to overcome drug resistance due to DNA repair mechanisms, are described.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: November 21, 2017
    Assignee: The University of Toledo
    Inventors: Stephan M. Patrick, Paul W. Erhardt, Christopher Trabbic
  • Patent number: 9809550
    Abstract: The invention provides quinolyl-hydrazones of Formula I, or pharmaceutically acceptable salts, esters, solvates, isomers and prodrugs thereof as well as pharmaceutical compositions containing these compounds for use in the prophylactic and/or therapeutic treatment of tuberculosis and related diseases, such as, diseases caused by nontuberculous mycobacteria and/or caused by Micobacterium leprae.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: November 7, 2017
    Assignee: TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
    Inventors: Ana Lucia Almeida Ferreira, Ana Sofia Lopes, Augusto Eugenio Pardal Filipe, Pedro Filipe Eufrasio Pedroso, Susana Marques De Almeida Pecorelli, Carlos Caixado
  • Patent number: 9781924
    Abstract: A synthetic polymer film includes a surface which has a plurality of first raised portions, wherein a two-dimensional size of the plurality of first raised portions is in a range of more than 20 nm and less than 500 nm when viewed in a normal direction of the synthetic polymer film; and the surface has a microbicidal effect.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: October 10, 2017
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Miho Yamada, Kiyoshi Minoura, Takahiro Nakahara, Seiji Takami
  • Patent number: 9770462
    Abstract: A method of treating ovarian, tubal and peritoneal cancer is revealed. It comprises administering an effective amount of a pharmaceutical composition (including a copper chelator, a platinum-based chemotherapeutic agent and an anthracycline) to a subject in need thereof for reducing concentration of intracellular copper ions and promoting activation of transcription factor Sp1 and human copper transporter 1 (hCTR1).
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: September 26, 2017
    Assignees: National Cheng Kung University, National Cheng Kung University Hospital
    Inventors: Cheng-Yang Chou, Tien-En Kuo, Yu-Fang Huang
  • Patent number: 9759698
    Abstract: An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with evaporative light scattering detection (ELSD); the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: September 12, 2017
    Assignee: Del Mar Pharmaceuticals
    Inventor: Xiaoyun Liu
  • Patent number: 9663484
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: May 30, 2017
    Assignee: MEI PHARMA, INC.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Patent number: 9649305
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignee: Advanced Cancer Therapeutics, LLC
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Patent number: 9630956
    Abstract: The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 25, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Hayley Marie Binch, Dennis James Hurley, Thomas Cleveland, Pramod Joshi, Lev Tyler Dewey Fanning, Joanne Pinder, Michael O'Donnell, Anisa Nizarali Virani, Ronald Marcellus Alphonsus Knegtel, Steven John Durrant, Stephen Clinton Young, Pierre-Henri Storck, David Kay, Philip Michael Reaper, Matthew Paul Grote
  • Patent number: 9623074
    Abstract: The invention provides a method for promoting wound healing or tissue injury treatment in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more fungal immunomodulatory protein (preferably, Ganoderma immunomodulatory protein).
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 18, 2017
    Assignee: 3D GLOBAL BIOTECH INC.
    Inventors: Keng-Liang Ou, Jungshan Chang
  • Patent number: 9593139
    Abstract: Compositions, kits, and methods for treatment of cancers are generally provided. In some embodiments, the compositions, kits, and methods comprise a platinum (e.g., Pt(II) or Pt(IV)) compound associated with a ligand (e.g., a beta-diketonate ligand) comprising a targeting moiety. Methods of synthesizing platinum (e.g., Pt(II) or Pt(IV)) compounds associated with a ligand comprising a targeting moiety are also provided.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: March 14, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Stephen J. Lippard, Justin J. Wilson, Robert John Radford, Maria R. Chan, Daniel Y. Zhang
  • Patent number: 9566280
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: February 14, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 9492418
    Abstract: Compounds used to inhibit glycolytic pathway small molecule kinase 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase (PFKFB) are set forth; these inhibitors can be used in the treatment of certain diseases in which cells or tumors rely on glycolytic metabolism, such as many cancer cells.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Yong-Hwan Lee, Jeong Do Kim
  • Patent number: 9458457
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 4, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 9415061
    Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of murmyl dipeptide, and their use in the treatment of neoplastic disease.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: August 16, 2016
    Assignee: Innate Immunotherapeutics Limited
    Inventors: Frank B Gelder, Gillian Alison Webster
  • Patent number: 9402847
    Abstract: The present invention relates to a combination comprising (5)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, hereafter “Compound (I)”, and a taxane. Taxanes include established cancer drugs such as docetaxel (Taxotere™) and paclitaxel (Taxol™). Such combinations may be useful in the treatment or prophylaxis of cancer. The invention also relates to a pharmaceutical composition comprising such Compound (I) and a taxane. The invention further relates to a method of treatment comprising the simultaneous, sequential or separate administration of Compound (I) and a taxane, to warm-blooded animal, such as man. The invention also relates to a kit comprising Compound (I) and a taxane, optionally with instructions for use.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 2, 2016
    Assignee: AstraZeneca AB
    Inventor: Barry Robert Davies
  • Patent number: 9320760
    Abstract: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: April 26, 2016
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventor: Frederick H. Hausheer
  • Patent number: 9316632
    Abstract: Methods for selecting chemotherapeutic agents for treating a cancer are provided that include the steps of providing a cancer cell sample having a population of bulk cancer cells and a population of cancer stem-like cells, culturing a first portion of the cancer cell sample in a hydrodynamic focusing bioreactor under microgravity conditions and for a period of time to selectively enhance the population of cancer stem-like cells and selectively kill the population of bulk cancer cells, contacting the cancer stem-like cells with one or more chemotherapeutic agents, and then selecting the one or more chemotherapeutic agents for treating the cancer if there is an increase in an amount of cytotoxicity. Methods for treating a cancer are also provided in which the identified chemotherapeutic agents are administered to a subject. Further provided are methods for identifying a test compound useful for treating a cancer.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: April 19, 2016
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Pier Paolo Claudio, Jagan Valluri
  • Patent number: 9186410
    Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: November 17, 2015
    Assignees: The University of British Columbia, Centre for Drug Research and Development
    Inventors: Helen Burt, Donald Brooks, Jayachandran Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
  • Patent number: 9180091
    Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: November 10, 2015
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Neda Irani, Janice Louise Cacace, Thorsteinn Thorsteinsson, Frederick D. Sancilio
  • Patent number: 9066918
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: June 30, 2015
    Assignee: Del Mar Pharmaceuticals
    Inventor: Dennis M. Brown
  • Publication number: 20150148870
    Abstract: The present invention discloses a method for preparing noble metal nanoparticles, comprising the following steps: a) preparing an Olea Europaea fruit extract; b) preparing an Acacia Nilotica extract; c) mixing the Olea Europaea fruit extract and the Acacia Nilotica extract for preparing a mixed extract; d) providing an aqueous solution containing a noble metal compound dissolved therein; e) mixing the mixed extract obtained in step c) and the aqueous solution of step d) to form noble metal nanoparticles; noble metal nanoparticles obtained thereby and their use.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 28, 2015
    Inventors: Awatif Ahmed HENDI, Manal A. AWAD, Nada E. EISA, Khaled M. ORTASHI
  • Publication number: 20150147314
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 28, 2015
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20150140122
    Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 21, 2015
    Applicant: INSERM (Institut National de la Sante et de la Rec herche)
    Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova
  • Publication number: 20150139946
    Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.
    Type: Application
    Filed: October 19, 2014
    Publication date: May 21, 2015
    Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat
  • Publication number: 20150140123
    Abstract: The invention relates to a method for screening compounds with (pro-)genotoxic activity by providing a system being capable of expressing a panel of defined proteins, incubating at least a portion of the system with compounds to be screened, and comparing the expression of the proteins in the system with the protein expression in a control system, thereby detecting the (pro-)genotoxic activity. Another object of the invention concerns a method for monitoring the likelihood of developing a physiological and/or pathological condition, which is caused, mediated and/or propagated by the genetic deregulation of proliferation, differentiation and/or damage repair, in response to a compound administered to a mammal in need of such treatment by determining an expression level of defined proteins in a biological sample withdrawn from the mammal. The invention also relates to a kit for screening compounds with (pro-)genotoxic activity comprising antibodies that specifically bind to marker proteins.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 21, 2015
    Inventors: Stefan Otto Mueller, Yasmin Dietz
  • Publication number: 20150140124
    Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 21, 2015
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Publication number: 20150140125
    Abstract: Synergistic cancer therapy drug combinations include therapeutically effective amounts of at least one chemotherapeutic drug or agent with a fortified decoction dosage form comprising from about 10 mg to about 6,000 mg each of ?-sitosterol, isovanillin, and linolenic acid. The decoction dosage preferably includes plant extract(s) of the genus Arum fortified with effective amounts of ?-sitosterol, isovanillin, and linolenic acid not derived from the plant. The combination may be in various forms including aqueous dispersions, gels, ampules, powders, capsules, pills, or tablets, and are normally administered orally to patients. The anticancer combinations have therapeutic effects on cancerous tissue which are greater than the sum of the individual therapeutic effects of the fortified decoction dosage form and the at least one chemotherapeutic agent on the cancerous tissue.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 21, 2015
    Inventors: Gene H. Zaid, Thomas W. Burgoyne, Lisa Stehno-Bittel, Mary Ann Lee-Stanislav
  • Publication number: 20150132298
    Abstract: The present invention provides compounds according to formula I: and pharmaceutically acceptable salts thereof. For compounds of formula I, R1 and R2 are independently selected from the group consisting of H, —C(?O)—(CH2)2-aryl, and —C(?O)—(CH2)n—C(?O)—NH-aryl. The subscript n is from 2 to 6. R3 is selected from the group consisting of H and —C(?O)—O—R4; and R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R1 and R2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Laurence I. Wu
  • Publication number: 20150132408
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 14, 2015
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue, Sung Hee Hwang
  • Patent number: 9029164
    Abstract: An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with evaporative light scattering detection (ELSD); the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: May 12, 2015
    Assignee: Del Mar Pharmaceuticals
    Inventors: Xiaoyun Lu, Mike Tso-Ping Li
  • Publication number: 20150125549
    Abstract: A method of treating large cell lung cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof, thereby treating the large cell lung cancer in the subject.
    Type: Application
    Filed: April 24, 2013
    Publication date: May 7, 2015
    Inventors: Amnon Peled, Ori Wald
  • Publication number: 20150125550
    Abstract: A method of inhibiting cancer cell growth is provided. In some versions, the method includes exposing lung cancer cells or glioma cells to 2,9-di-sec-butyl-1,10-phenanthroline (SBP) or derivatives of SBP in an amount effective to inhibit glioma cell growth. Also, a method of treating a lung cancer or a glioma tumor in a subject in need of such treatment is provided. The method includes administering SBP or derivatives of SBP to the subject in an amount effective to treat the lung cancer or glioma tumor. For either method, the method can further include exposing or administering pseudo five coordinate gold(III) complexes of SBP derivatives.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 7, 2015
    Inventors: Jack F. Eichler, Clement N. David, Emma H. Wilson
  • Patent number: 9023787
    Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 5, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Isaac A. Manke, Hans Christian Reinhardt
  • Publication number: 20150118322
    Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 30, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU